Olanzapine vs. Lamotrigine: side effect and effectiveness comparison (a real world drug study)
Summary:
We compare the side effects and drug effectiveness of Olanzapine and Lamotrigine. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 282,521 people who take Olanzapine and Lamotrigine, and is updated regularly.
What is Olanzapine?
Olanzapine has active ingredients of olanzapine. It is often used in bipolar disorder. eHealthMe is studying from 69,242 Olanzapine users. Check the latest studies of Olanzapine.
What is Lamotrigine?
Lamotrigine has active ingredients of lamotrigine. It is often used in bipolar disorder. eHealthMe is studying from 76,639 Lamotrigine users. Check the latest studies of Lamotrigine.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
282,521 people who take Olanzapine and Lamotrigine are studied.
Drugs being compared in this study:
- Olanzapine (olanzapine)
- Lamotrigine (lamotrigine)
Most common side effects of the drugs, overall:
Most common side effects of the drugs, in long term (1+ years) use:
Drug effectiveness:
Olanzapine:
- not at all: 6.95 %
- somewhat: 24.56 %
- moderate: 34.05 %
- high: 24.27 %
- very high: 10.18 %
Lamotrigine:
- not at all: 3.22 %
- somewhat: 16.72 %
- moderate: 30.64 %
- high: 32.53 %
- very high: 16.9 %
Want to compare Olanzapine with Lamotrigine?
- Personalize this study to your gender and age (0-99+)How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies
- Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
- Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
- Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
- Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .
- Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
- Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
- Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
- Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .
Related studies
Alternative drugs to, pros and cons of:
- Olanzapine (68,595 reports)
- Lamotrigine (72,845 reports)
Browse all side effects of Olanzapine:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Lamotrigine:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study is based on olanzapine and lamotrigine (the active ingredients of Olanzapine and Lamotrigine, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Cognex cause Weakness? - a second ago
- Could Bosentan cause Arthritis? - 6 seconds ago
- Could Beconase cause Pain Exacerbated? - 8 seconds ago
- Could Elavil cause Headache? - 11 seconds ago
- Could Colace cause Birth Control? - 13 seconds ago
- Drug interactions of Xyrem and D-Ribose - 13 seconds ago
- Could Tazorac cause Intestinal Obstruction? - 13 seconds ago
- Could Elavil cause Osteopenia? - 14 seconds ago
- Could Orphenadrine Citrate cause Peripheral Swelling? - 18 seconds ago
- Could Taltz cause Paraesthesia? - 19 seconds ago